|
Index of reports
> Cases with Hypertension (17)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Hydrocortisone (Hydrocortisone Topical) where reactions include hypertension. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Hydrocortisone side effects in
Reported by a physician from United States on 2012-08-22
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Coagulopathy, Hypoglycaemia, Hypocalcaemia, Hypoxia, Hiccups, Alanine Aminotransferase Abnormal, Pneumonitis, Cough, Pain in Extremity, Hypotension, Hyperglycaemia, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate Sodium
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Vancomycin; Posaconazole; Voriconazole; Levofloxacin
Possible Hydrocortisone side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypokalaemia, Blood Bilirubin Abnormal, Hiccups, Pleural Effusion, Hypoxia, Hypocalcaemia, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Decreased Appetite, Pain in Extremity, Hypotension, Hyperglycaemia, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, External Ear Pain, Hypercalcaemia, Haematotoxicity, Hypophosphataemia, Diarrhoea, Dehydration, Hypoalbuminaemia, Lower Gastrointestinal Haemorrhage, Hypertension, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Voriconazole; Posaconazole; Vancomycin
Possible Hydrocortisone side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Off Label Use, Hypotension, Hypertension
Drug(s) suspected as cause:
Bortezomib
Dosage: per dose on days 1, 4, 8 and 11
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 or days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: per day divided into 2 doses was given orally for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: on day 15 or days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Dosage: 2500 units/m2/dose was given intramuscularly as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: per dose (2 mg maximum dose) was administered intravenously by push on day 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Possible Hydrocortisone side effects in
Reported by a physician from United States on 2012-08-14
Patient:
Reactions: Thrombosis, Abdominal Pain, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypoxia, Hypocalcaemia, Hiccups, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Pain in Extremity, Hyperglycaemia, Hypotension, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Neuropathy Peripheral, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Hyponatraemia, Gamma-Glutamyltransferase Abnormal, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Vancomycin; Posaconazole; Voriconazole
Possible Hydrocortisone side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Methotrexate
Dosage: 3000 mg/m2; administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Methotrexate
Dosage: as part of copadm2 and cym1
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm1
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Possible Hydrocortisone side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Methotrexate
Dosage: as part of copadm2 and cym1
Methotrexate
Dosage: administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm1
Possible Hydrocortisone side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-21
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: six doses as part of copadm1 and six doses as part of dose-reduced copadm2
Cyclophosphamide
Dosage: 300 mg/m2 as part of cop
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: continuous infusion of 100 mg/m2 daily for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: administered once with hydrocortisone as part of cym1
Doxorubicin HCL
Dosage: as part of copadm1
Indication: Burkitt's Lymphoma Stage III
Doxorubicin HCL
Dosage: as part of copadm2
Hydrocortisone
Dosage: administered once with cytarabine as part of cym1
Hydrocortisone
Dosage: administered with methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm2 and cym1
Methotrexate
Dosage: administered with hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: as part of copadm1
Prednisolone
Dosage: 60 mg/m2/day for 7 days as part of cop
Indication: Burkitt's Lymphoma Stage III
Prednisolone
Dosage: 60 mg/m2/day for 5 days, then tapered over 3 days as part of copadm1 and copadm2
Rituximab
Dosage: five total doses; cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: as part of copadm2
Vincristine
Dosage: as part of copadm1
Vincristine
Dosage: as part of cop
Indication: Burkitt's Lymphoma Stage III
Possible Hydrocortisone side effects in 10 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-20
Patient: 10 year old female
Reactions: Small Intestinal Obstruction, Renal Failure, Sepsis, Pancytopenia, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 250 mg/m2, bid for 6 doses
Cyclophosphamide
Dosage: 250 mg/m2, bid for 6 doses
Cyclophosphamide
Dosage: 300 mg/m2, unk
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: 100 mg/m2, for 5 days
Indication: Burkitt's Lymphoma Stage III
Cytarabine
Dosage: unknown
Doxorubicin HCL
Dosage: 30 mg/m2, unk
Doxorubicin HCL
Dosage: 60 mg/m2, unk
Indication: Burkitt's Lymphoma Stage III
Hydrocortisone
Indication: Burkitt's Lymphoma Stage III
Hydrocortisone
Dosage: intrathecally twice
Hydrocortisone
Hydrocortisone
Dosage: intrathecally twice
Hydrocortisone
Dosage: unknwon
Methotrexate
Dosage: 1500 mg/m2, unk
Methotrexate
Indication: Burkitt's Lymphoma Stage III
Methotrexate
Dosage: intrathecally twice
Methotrexate
Dosage: intrathecally twice
Methotrexate
Dosage: 1500 mg/m2, unk
Methotrexate
Dosage: 30000 mg/m2, unk
Methotrexate
Prednisolone
Dosage: 60 mg/m2, for 5 days, then taper over 3 days
Prednisolone
Dosage: 60 mg/m2, for 5 days then taper over 3 days
Prednisolone
Dosage: 60 mg/m2, per day for 7 days
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: every 2-4 weeks for 5 total doses with cumulative dose of 1875 mg/m2
Indication: Burkitt's Lymphoma Stage III
Rituximab
Dosage: cumulative dose of 1875 mg/m2
Vincristine
Dosage: 2 mg/m2, unk
Vincristine
Dosage: 1 mg/m2, unk
Indication: Burkitt's Lymphoma Stage III
Vincristine
Dosage: 1 mg/m2, unk
Possible Hydrocortisone side effects in 10 year old female
Reported by a individual with unspecified qualification from United States on 2012-04-26
Patient: 10 year old female
Reactions: Renal Failure, Sepsis, Febrile Neutropenia, Hypertension, Abdominal Compartment Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: regimen copadm1, for 6 doses
Cyclophosphamide
Dosage: regimen cop
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: regimen copadm2, for 6 doses
Cytarabine
Dosage: regimen cym1,continuous infusion daily for 5 days
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Dosage: regimen copadm2
Doxorubicin HCL
Dosage: regimen copadm1
Indication: Burkitt's Lymphoma
Hydrocortisone
Dosage: regimen cym1, methotrexate/hydrocortisone once and cytarabine/hydrocortisone once
Hydrocortisone
Dosage: regimen copadm2, methotrexate/hydrocortisone twice
Hydrocortisone
Dosage: regimen cop, methotrexate/hydrocortisone
Indication: Burkitt's Lymphoma
Hydrocortisone
Dosage: regimen copadm1, methotrexate/hydrocortisone twice
Methotrexate
Dosage: regimen copadm2
Methotrexate
Dosage: regimen copadm1,
Indication: Burkitt's Lymphoma
Methotrexate
Dosage: regimen cym1
Prednisolone
Dosage: regimen copadm1, for 5 days then taper over 3 days
Prednisolone
Dosage: regimen copadm2, for 5 days then taper over 3 days
Prednisolone
Dosage: regimen cop, for 7 days
Indication: Burkitt's Lymphoma
Rituximab
Dosage: every 2-4 weeks for 5 total doses, starting between copadm1 and copadm2
Indication: Burkitt's Lymphoma
Vincristine
Dosage: regimen copadm1
Vincristine
Dosage: regimen cop
Indication: Burkitt's Lymphoma
Vincristine
Dosage: regimen copadm2
Possible Hydrocortisone side effects in female
Reported by a physician from Germany on 2012-02-22
Patient: female, weighing 60.0 kg (132.0 pounds)
Reactions: Headache, Horner's Syndrome, Haematemesis, Metastasis, Electrolyte Imbalance, Thrombocytopenia, Epistaxis, Back Pain, Vomiting, Adrenocortical Insufficiency Acute, Nausea, Anaemia, Neutropenic Sepsis, Hyponatraemia, Pancytopenia, Neoplasm Malignant, Disturbance in Attention, Hypertension
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cisplatin
Dosage: unk
Indication: Neoplasm Malignant
Start date: 2011-03-23
End date: 2011-03-25
Etoposide
Dosage: unk
Indication: Neoplasm Malignant
Start date: 2011-03-25
End date: 2011-03-25
Hydrocortisone
Dosage: 3 mg, unk
Administration route: Oral
Start date: 2008-12-15
Morphine
Som230
Dosage: 60 mg, unk
Indication: Neuroendocrine Tumour
Start date: 2010-06-15
End date: 2011-01-26
Voltaren
Dosage: unk
Start date: 2011-02-01
Other drugs received by patient: Zoledronic; Astonin-H
Possible Hydrocortisone side effects in 69 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2011-12-06
Patient: 69 year old female
Reactions: Acute Pulmonary Oedema, Herpes Simplex, Cytomegalovirus Infection, Cardiomyopathy, Hypertension
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Doxorubicin HCL
Dosage: 50 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Hydrocortisone
Dosage: 25 mg, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Mabthera
Dosage: 375 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Methotrexate
Dosage: 15 mg, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Prednisone TAB
Dosage: unk
Administration route: Oral
Start date: 2011-07-07
End date: 2011-07-10
Solu-Medrol
Dosage: 40 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Vincristine Sulfate
Dosage: 1.4 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Possible Hydrocortisone side effects in 69 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2011-12-01
Patient: 69 year old female
Reactions: Acute Pulmonary Oedema, Herpes Simplex, Cytomegalovirus Infection, Cardiomyopathy, Hypertension
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Doxorubicin HCL
Dosage: 50 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Hydrocortisone
Dosage: 25 mg, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Mabthera
Dosage: 375 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Methotrexate
Dosage: 15 mg, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Prednisone TAB
Dosage: unk
Administration route: Oral
Start date: 2011-07-07
End date: 2011-07-10
Solu-Medrol
Dosage: 40 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Vincristine Sulfate
Dosage: 1.4 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Possible Hydrocortisone side effects in female
Reported by a physician from Germany on 2011-11-17
Patient: female, weighing 60.0 kg (132.0 pounds)
Reactions: Headache, Horner's Syndrome, Haematemesis, Metastasis, Electrolyte Imbalance, Thrombocytopenia, Epistaxis, Back Pain, Vomiting, Nausea, Adrenocortical Insufficiency Acute, Neutropenic Sepsis, Anaemia, Hyponatraemia, Pancytopenia, Neoplasm Malignant, Disturbance in Attention, Hypertension
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cisplatin
Dosage: unk
Indication: Neoplasm Malignant
Start date: 2011-03-23
End date: 2011-03-25
Etoposide
Dosage: unk
Indication: Neoplasm Malignant
Start date: 2011-03-25
End date: 2011-03-25
Hydrocortisone
Dosage: 3 mg, unk
Administration route: Oral
Start date: 2008-12-15
Morphine
Som230
Dosage: 60 mg, unk
Indication: Neuroendocrine Tumour
Start date: 2010-06-15
End date: 2011-01-26
Voltaren
Dosage: unk
Start date: 2011-02-01
Other drugs received by patient: Astonin-H; Zoledronic
Possible Hydrocortisone side effects in female
Reported by a physician from Germany on 2011-11-11
Patient: female, weighing 60.0 kg (132.0 pounds)
Reactions: Headache, Haematemesis, Horner's Syndrome, Metastasis, Electrolyte Imbalance, Thrombocytopenia, Epistaxis, Back Pain, Vomiting, Nausea, Adrenocortical Insufficiency Acute, Anaemia, Pancytopenia, Hyponatraemia, Neoplasm Malignant, Disturbance in Attention, Hypertension
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Diclofenac Sodium
Dosage: unk
Start date: 2011-02-01
Hydrocortisone
Morphine
Som230
Dosage: 60 mg, unk
Indication: Neuroendocrine Tumour
Start date: 2010-06-15
End date: 2011-02-01
Other drugs received by patient: Astonin-H; Zoledronic
Possible Hydrocortisone side effects in 22 year old female
Reported by a physician from United States on 2011-11-10
Patient: 22 year old female
Reactions: White Blood Cell Count Decreased, Headache, Neutrophil Count Decreased, Hypertension, Enterocolitis Infectious, Fluid Retention
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Indication: Lymphocytic Leukaemia
Cyclophosphamide
Dosage: 2400 mg total
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Cytarabine
Indication: Lymphocytic Leukaemia
Dasatinib
Dosage: 1400 mg
Administration route: Oral
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Daunorubicin Hydrochloride
Indication: Lymphocytic Leukaemia
Dexamethasone
Administration route: Oral
Indication: Lymphocytic Leukaemia
Etoposide
Dosage: 800 mg total
Indication: Lymphocytic Leukaemia
Start date: 2011-05-28
Hydrocortisone
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Ifosfamide
Indication: Lymphocytic Leukaemia
Mercaptopurine
Dosage: 2475 mg total dose
Administration route: Oral
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Methotrexate
Dosage: 8127.5 mg total
Administration route: Oral
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Metronidazole
Indication: Lymphocytic Leukaemia
Pegaspargase
Indication: Lymphocytic Leukaemia
Prednisone TAB
Dosage: 600 mg
Administration route: Oral
Indication: Lymphocytic Leukaemia
Vincristine
Indication: Lymphocytic Leukaemia
Possible Hydrocortisone side effects in 22 year old female
Reported by a physician from United States on 2011-11-10
Patient: 22 year old female
Reactions: White Blood Cell Count Decreased, Headache, Hypertension, Neutrophil Count Decreased, Fluid Retention, Enterocolitis Infectious
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 480 mg (total dose: 2400 mg: 300 mg/m2/dose)
Start date: 2011-09-11
Cyclophosphamide
Dosage: 2400 mg, unk
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Cytarabine
Dosage: 60 mg, unk
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Cytarabine
Dosage: 30 mg (total dose: 60 mg) given it
Start date: 2011-09-07
Dasatinib
Dosage: 1400 mg, unk
Administration route: Oral
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Dasatinib
Dosage: unk
Start date: 2011-06-17
Dasatinib
Dosage: 100 mg, 1x/day (total dose: 1400 mg) qd x 14 days (60 mg/m2/dose) on maintenance cycle 3
Administration route: Oral
Start date: 2011-09-20
Daunorubicin Hydrochloride
Indication: Lymphocytic Leukaemia
Dexamethasone Sodium Phosphate
Dosage: unk
Administration route: Oral
Indication: Lymphocytic Leukaemia
Dexamethasone Sodium Phosphate
Dosage: 2 mg, on days 1 and 29 of maintenance cycle 3
Start date: 2011-09-07
Elspar
Indication: Lymphocytic Leukaemia
Etoposide
Dosage: 160 mg (total dose 800 mg: 100 mg/m2/dose) on days 29-33
Start date: 2011-09-11
Etoposide
Dosage: 800 mg, unk
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Flagyl
Dosage: unk
Indication: Clostridium Difficile Colitis
Start date: 2011-06-18
End date: 2011-06-22
Hydrocortisone
Dosage: 30 mg, unk
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Hydrocortisone
Dosage: 15 mg (total dose: 30 mg)
Start date: 2011-09-07
Ifosfamide
Indication: Lymphocytic Leukaemia
Mercaptopurine
Dosage: 125 mg x 5 days each week and 100 x 2 days each week, repeated for 3 weeks total (days 8-28)
Start date: 2011-09-06
Mercaptopurine
Dosage: 2475 mg, unk
Administration route: Oral
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Methotrexate Sodium
Dosage: 8127.5 mg, unk
Administration route: Oral
Indication: Lymphocytic Leukaemia
Start date: 2010-05-28
Methotrexate Sodium
Dosage: unk
Start date: 2011-06-17
Methotrexate Sodium
Dosage: 8000 mg (5000 mg/m2/dose) given as 24 hour infusion on day 1 and 15 mg it on days 1 and 29
Start date: 2011-08-12
Pegaspargase
Indication: Lymphocytic Leukaemia
Prednisone
Dosage: 600 mg, unk
Administration route: Oral
Indication: Lymphocytic Leukaemia
Start date: 2011-06-17
Prednisone
Dosage: 30 mg 2x/day (20 mg/m2/dose) on days 1-5 and on days 29-33 of maintenance cycle 3
Administration route: Oral
Start date: 2011-09-11
Vincristine Sulfate
Dosage: 4 mg, unk
Indication: Lymphocytic Leukaemia
Start date: 2011-06-17
Possible Hydrocortisone side effects in 69 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2011-10-24
Patient: 69 year old female
Reactions: Acute Pulmonary Oedema, Herpes Simplex, Cytomegalovirus Infection, Cardiomyopathy, Hypertension, Acute Respiratory Failure
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Doxorubicin HCL
Dosage: 50 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Hydrocortisone
Dosage: 25 mg, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Mabthera
Dosage: 375 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Methotrexate
Dosage: 15 mg, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Prednisone
Dosage: unk
Administration route: Oral
Start date: 2011-07-07
End date: 2011-07-10
Solu-Medrol
Dosage: 40 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
Vincristine Sulfate
Dosage: 1.4 mg/m2, unk
Indication: T-Cell Lymphoma Stage III
Start date: 2011-07-06
End date: 2011-07-06
|
